Neurodegenerative Disease Therapeutics Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Neurodegenerative Disease Therapeutics Market Overview

Neurodegenerative disease therapeutics continue to advance through targeted treatment approaches that address progressive neurological disorders, improve symptom management, and support long-term patient care. Ongoing research is expanding therapeutic options with greater emphasis on disease modification and personalized treatment strategies. The market is poised to grow at a CAGR of 7.00% during the forecast period of 2026-2035, driven by the rising prevalence of neurodegenerative disorders, increasing investments in neurological research, expanding clinical development pipelines, and growing adoption of innovative therapies. Favorable regulatory support and advancements in precision medicine further strengthen market expansion.

Neurodegenerative Disease Therapeutics Market Growth Analysis and Key Influencers

Neurodegenerative Disease Therapeutics Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Neurodegenerative Disease Therapeutics Market Growth Drivers

Rising Prevalence of Neurodegenerative Disorders is Accelerating Market Expansion

The increasing prevalence of neurodegenerative disorders is a major factor driving the market, as the growing patient population continues to increase the demand for effective therapeutic interventions. Aging populations, longer life expectancy, and improved disease recognition are further contributing to treatment demand. According to Dongning Su et al., 2025, the global number of people living with Parkinson's disease is projected to reach 25.2 million by 2050, representing a 112% increase from 2021, primarily driven by population aging. This rising disease burden is expected to strengthen therapeutic development and support sustained market expansion.

Neurodegenerative Disease Therapeutics Market Restraints

High Development Costs and Limited Therapeutic Success Continue to Challenge the Market

The market faces significant challenges due to the high cost of drug development, lengthy clinical trials, and the low success rate of therapies targeting complex neurodegenerative disorders. Many investigational drugs fail to demonstrate sufficient clinical efficacy, resulting in increased research expenditures and delayed commercialization. These challenges discourage investment, limit the availability of novel therapies, and slow the introduction of innovative treatment options, thereby restricting the overall expansion of the market.

Neurodegenerative Disease Therapeutics Market Opportunities

Growing Collaborative Research Initiatives are Creating New Avenues for the Market

Expanding global collaborations focused on neuroscience research are creating significant potential for the market by accelerating the discovery and development of innovative therapies. For instance, in June 2026, the Allen Institute launched the Brain Health accelerator, a global research initiative supported by approximately USD 400 million in funding to advance precision treatments for neurodegenerative diseases through collaborative research, artificial intelligence, and advanced genomic technologies. Such initiatives are expected to enhance therapeutic innovation and create long-term growth prospects for the market.

Neurodegenerative Disease Therapeutics Market Trends

The market is witnessing several trends, including increased therapeutic innovation, strategic research collaborations, and precision medicine development.

Increasing Investment in Novel Therapeutic Development is Enhancing Market Value

The growing investments in innovative therapeutic research are reshaping the market by encouraging the development of next-generation treatments for neurodegenerative disorders. For example, in May 2026, BSM Biotech Holdings invited global discovery-stage projects focused on neurodegeneration, supporting the creation of biotechnology companies developing novel therapeutic candidates. This increasing emphasis on early-stage innovation is expected to accelerate drug development and strengthen the long-term growth of the market.

Neurodegenerative Disease Therapeutics Market Share

Alzheimer's Disease Segment is Expected to Lead Indication Segmentation in the Market

The market is segmented by indication into Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington disease, and others. Among these, Alzheimer's disease is expected to account for the largest market share due to its rapidly increasing global prevalence, expanding aging population, and rising demand for disease-modifying therapies. According to Ruixue Qin et al., 2025, approximately 56.9 million people worldwide are living with Alzheimer's disease and related dementias, with the number projected to reach 152.8 million by 2050. This expanding patient population is anticipated to sustain the dominance of the Alzheimer's Disease segment throughout the forecast period.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Neurodegenerative Disease Therapeutics Market Analysis by Region

The regions covered in the report include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Among these, North America is expected to lead the market due to its strong biotechnology ecosystem, significant research investments, favorable funding environment, and continuous development of innovative therapies. For instance, in March 2026, NeurOdys Therapeutics launched operations with support from international investors to advance artificial intelligence-driven small molecule therapies for neurodegenerative diseases, reflecting the region's robust innovation landscape. These factors are expected to reinforce North America's leading position in the market.

Leading Players in the Neurodegenerative Disease Therapeutics Market

Neurodegenerative Disease Therapeutics Market Segmentation

Key Questions Answered in the Neurodegenerative Disease Therapeutics Market Report

• What was the neurodegenerative disease therapeutics market value in 2025?
• What is the neurodegenerative disease therapeutics market forecast outlook for 2026-2035?
• What are the major factors aiding the neurodegenerative disease therapeutics market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major neurodegenerative disease therapeutics market trends?
• Which indication is expected to dominate the market segment?
• Which drug type is projected to lead the market segment?
• Which distribution channel is anticipated to drive the market segment?
• Who are the key players involved in the neurodegenerative disease therapeutics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth interviews conducted with 30+ neurologists, neurodegenerative disease specialists, hospital pharmacy procurement managers, clinical researchers, and payer representatives across the US, EU5, and Japan, including key opinion leaders (KOLs) affiliated with the American Academy of Neurology (AAN), Alzheimer's Association, Parkinson's Foundation, and European Academy of Neurology (EAN).
• Secondary Research: Peer-reviewed publications from The Lancet Neurology, JAMA Neurology, Nature Reviews Neurology, and Neurology; regulatory filings from the FDA, EMA, PMDA, and CDSCO; clinical trial data from ClinicalTrials.gov; epidemiological data from the WHO, CDC, NIH, and the Global Burden of Disease Study; and company annual reports, investor presentations, pipeline updates, SEC filings, and official company websites.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling and validated through iterative expert review, company benchmarking, and continuous feedback from industry specialists.